Lupin is currently trading at Rs. 1197.00, up by 3.20 points or 0.27% from its previous closing of Rs. 1193.80 on the BSE.

The scrip opened at Rs. 1180.65 and has touched a high and low of Rs. 1211.10 and Rs. 1180.65 respectively. So far 15923 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 1238.15 on 09-Nov-2023 and a 52 week low of Rs. 628.10 on 31-Mar-2023.

Last one week high and low of the scrip stood at Rs. 1211.10 and Rs. 1153.55 respectively. The current market cap of the company is Rs. 54634.32 crore.

The promoters holding in the company stood at 47.06%, while Institutions and Non-Institutions held 44.42% and 8.52% respectively.

Lupin has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Ganirelix Acetate Injection, 250 mcg/0.5 mL Single-Dose Prefilled Syringe, to market a generic equivalent to the reference listed drug (RLD), of Ganirelix Acetate Injection, 250 mcg/0.5 mL of Organon USA LLC. Ganirelix is Lupin’s first peptide-based injectable, strengthening the Company’s commitment to innovative healthcare solutions.

The product will be manufactured at Lupin’s Nagpur facility in India. Ganirelix Acetate Injection is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation. Ganirelix Acetate Injection had estimated annual sales of $84 million in the U.S. (IQVIA MAT September 2023).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.